Ceftibuten

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of Ceftibutene
General
Non-proprietary name Ceftibuten
other names

(+) - (6 R , 7 R ) -7 - [( Z ) -2- (2-Aminothiazol-4-yl) -4-carboxycrotonamido] -8-oxo-5-thia-1-azabicyclo [4.2. 0] oct-2-en-2-carboxylic acid ( IUPAC )

Molecular formula C 15 H 14 N 4 O 6 S 2
External identifiers / databases
CAS number 97519-39-6
EC number 810-182-0
ECHA InfoCard 100.238.211
PubChem 5282242
ChemSpider 4445419
DrugBank DB01415
Wikidata Q419521
Drug information
ATC code

J01 DD14

Drug class

β-lactam antibiotics
(3rd generation cephalosporins)

properties
Molar mass 410.43 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
08 - Dangerous to health 07 - Warning

danger

H and P phrases H: 332-334
P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ceftibuten is a drug from the group of third-generation cephalosporins , which belong to the β-lactam antibiotics . It is used to treat bronchitis , sinusitis (sinus infection), and infections of the kidney , tonsils , throat, and middle ear . It is also used as oral continuation therapy when intravenous cephalosporins are no longer necessary for sustained treatment. Ceftibuten was patented by Shionogi in 1985 , the dihydrate is used .

Spectrum of activity

Not effective against Staphylococcus aureus . Only partially effective against pneumococci (Streptococcus pneumoniae) and B streptococci (Streptococcus agalactiae). Effective against Streptococcus pyogenes , Haemophilus influenzae , Moraxella catarrhalis , Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis and other Enterobacteriaceae . The extended half-life and the high β-lactamase stability are advantageous.

application

Ceftibuten is administered orally as a dihydrate.

Side effects

Occasionally, headache, hypersensitivity, white blood count disorders ( leukopenia , eosinophilia , thrombocytopenia ) and an increase in liver enzymes occur. Vomiting , diarrhea , gastritis and other gastrointestinal complaints can rarely occur.

Trade names

Monopreparations

Caedax (D, A), Cedax (D, CH), Keimax (D, except trade)

Individual evidence

  1. ↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A label of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on December 28, 2019, is derived from a self-classification by the distributor .
  2. ↑ entry to ceftibuten. In: Römpp Online . Georg Thieme Verlag, accessed on March 3, 2014.
  3. ↑ SCHOLZ, H., NABER, KG and the expert group of the Paul Ehrlich Society for Chemotherapy e. V., Chemietherapie Journal 1999 ; 8: 227–229 (PDF) ( Memento from September 20, 2009 in the Internet Archive )
  4. ↑ Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V., Chemotherapy Journal 2006 ; 15: 129–145 (PDF) ( Memento from September 20, 2009 in the Internet Archive )